#Gastric Cancer – Diseases & Therapeutic Pipeline Review
Text
Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact) published on
https://www.sandlerresearch.org/helicobacter-pylori-tests-in-vitro-diagnostics-global-market-analysis-and-forecast-model-covid-19-market-impact.html
Helicobacter Pylori Tests (In Vitro Diagnostics) - Global Market Analysis and Forecast Model (COVID-19 market impact)
Helicobacter Pylori Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact)
Summary
Helicobacter Pylori Tests (In Vitro Diagnostics) – Global Market Analysis and Forecast Model (COVID-19 market impact) is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on Helicobacter Pylori Tests market for the year 2020 and beyond. H. pylori has been recognized as a Class I carcinogen by the International Agency for Research on Cancer and as one of the strongest known risk factors for gastric malignancies like peptic ulcer disease, gastric MALT lymphoma and gastric cancer as 89% of all gastric cancers are related to H. pylori infection.
The occurrence of infection is mainly observed during childhood in large number of population. It gets transmitted from mother-to-child in developed countries, but horizontal transmission is not observed in developed countries due to better sanitary conditions.
The prevalence is lower in developed nations with a prevalence rate of 15.5% when compared to the developing countries having a prevalence rate of 93.6%. The main causes for the high prevalence of infection are poverty enhanced level of transmission due to malnutrition, poor hygiene and unaffordable heath care indicating low socioeconomic status in regions like Asia, South America and Africa. Helicobacter Pylori Tests is segmented into Helicobacter pylori Breath Test, Helicobacter pylori Feces Test, Helicobacter pylori IHC Test, Helicobacter pylori Serology EIA Test, Helicobacter Pylori Point of Care (POC) Tests and Helicobacter Pylori Other Tests.
Each of the covered 39 country’s color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are –
Currently marketed Helicobacter Pylori Tests and evolving competitive landscape –
– Insightful review of the key industry trends.
– Annualized total Helicobacter Pylori Tests market revenue by segment and market outlooks from 2015-2030.
– Granular data on total procedures, units, average selling prices and market values by segment.
Global, Regional and Country level market specific insights –
– Qualitative market specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country specific insights on the market.
– SWOT analysis for Helicobacter Pylori Tests market.
– Competitive dynamics insights and trends provided for Helicobacter Pylori Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
– Country specific overview of the healthcare system.
– Country specific reimbursement policies.
– Country specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered – Otsuka Holdings Co Ltd, Avanos Medical Inc, Abbott Laboratories, Meridian Bioscience Inc, DiaSorin SpA, Thermo Fisher Scientific Inc., and Others
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina and Chile.
Scope
Who should buy this report?
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for –
– CMO executives who must have deep understanding of the Helicobacter Pylori Tests market place to make strategic planning and investment decisions.
– Sourcing and procurement executives who must understand crucial components of the supply base in order to make decisions about supplier selection and management.
– Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to –
– Understand the impact of COVID-19 on Helicobacter Pylori Tests market.
– Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
– Develop business strategies by understanding the trends shaping and driving Helicobacter Pylori Tests market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Helicobacter Pylori Tests market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analysing the company share of market leaders.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track device sales in the global and country-specific Helicobacter Pylori Tests market from 2015-2030.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
0 notes
Text
Gastric Cancer – Diseases & Therapeutic Pipeline Review, H2 2017 Covering Key Players Tyrogenex, United BioPharma, Vaxon Biotech
A new research document with title 'Gastric Cancer - Pipeline Review, H2 2017' covering detailed analysis, Competitive landscape, forecast and strategies. The study covers geographic analysis and important players/vendors such as Tyrogenex, United BioPharma, Vaxon Biotech etc. The report will help user gain market insights, future trends and growth prospects for forecast.
Request a sample report @ https://www.htfmarketreport.com/sample-report/772412-gastric-cancer-pipeline-review-1
The latest Pharmaceutical and Healthcare disease pipeline guide Gastric Cancer - Pipeline Review, H2 2017, provides an overview of the Gastric Cancer (Oncology) pipeline landscape.
Gastric cancer, also called stomach cancer, is a malignant tumor arising from the lining of the stomach. Signs and symptoms of gastric cancer include fatigue, stomach pain, vomiting, weight loss that is unintentional, feeling bloated after eating, heartburn and indigestion. Risk factors include smoking, pernicious anemia, stomach polyps, infection with helicobacter pylori and family history of stomach cancer. Treatment includes surgery, chemotherapy and radiation therapy.
Report Highlights
The Pharmaceutical and Healthcare latest pipeline guide Gastric Cancer - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Gastric Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Gastric Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Gastric Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 5, 2, 14, 72, 87, 6, 84, 14 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 8, 4, 11 and 1 molecules, respectively.
Gastric Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Gastric Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Gastric Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Gastric Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Gastric Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Gastric Cancer (Oncology)
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=772412
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Gastric Cancer (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Gastric Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report
3SBio Inc, AbbVie Inc, AbGenomics International Inc, Abion Inc, Adaptimmune Therapeutics Plc, ADC Therapeutics Sarl, Aduro BioTech Inc, Advenchen Laboratories LLC, Allist Shanghai Pharmaceutical Technology Co Ltd, Almac Discovery Ltd, Alteogen Inc, Ambrx Inc, amcure GmbH, Amgen Inc, ANP Technologies Inc, Antikor Biopharma Ltd, arGEN-X BV, Array BioPharma Inc, Asana BioSciences LLC, Aslan Pharmaceuticals Pte Ltd, Astellas Pharma Inc, AstraZeneca Plc, Athenex Inc, Basilea Pharmaceutica Ltd, Bayer AG, BeiGene Ltd, Beijing Hanmi Pharmaceutical Co Ltd, Betta Pharmaceuticals Co Ltd, Biocon Ltd, Bioleaders Corp, Bionovis SA, Boehringer Ingelheim GmbH, Bristol-Myers Squibb Co, Camel-IDS NV, Cancer Prevention Pharmaceuticals Inc, Cascadian Therapeutics Inc, CBT Pharmaceuticals Inc, Celgene Corp, Celldex Therapeutics Inc, Cellectar Biosciences Inc, Celltrion Inc, Celon Pharma SA, Chipscreen Biosciences Ltd, Chugai Pharmaceutical Co Ltd, Curaxys SL, Cytori Therapeutics Inc, Daiichi Sankyo Co Ltd, Debiopharm International SA, Deciphera Pharmaceuticals LLC, Dr. Reddy's Laboratories Ltd, Eddingpharm Inc, Eli Lilly and Co, EOS Biosciences Inc, Erytech Pharma SA, Esperance Pharmaceuticals Inc, Exelixis Inc, F-star Biotechnology Ltd, F. Hoffmann-La Roche Ltd, Five Prime Therapeutics Inc, Frost Biologic Inc, Galena Biopharma Inc, Genelux Corp, Genentech Inc, Gilead Sciences Inc, GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd, GlycoNex Inc, Glycotope GmbH, Green Cross Corp, Halozyme Therapeutics Inc, Hanmi Pharmaceuticals Co Ltd, Horizon Pharma Plc, Humanigen Inc, Hummingbird Bioscience Pte Ltd, Hutchison MediPharma Ltd, Ignyta Inc, Ildong Pharmaceutical Co Ltd, Immunomedics Inc, Incyte Corp, Inovio Pharmaceuticals Inc, Inspyr Therapeutics Inc, Insys Therapeutics Inc, Ipsen SA, Jiangsu Hengrui Medicine Co Ltd, Jiangsu Kanion Pharmaceutical Co Ltd, Johnson & Johnson, Jounce Therapeutics Inc, Konruns Pharmaceutical Co Ltd, Kringle Pharma Inc, Kuhnil Pharmaceutical Co Ltd, Kyowa Hakko Kirin Co Ltd, LATITUDE Pharmaceuticals Inc, LegoChem Biosciences Inc, LinXis BV, MacroGenics Inc, Madrigal Pharmaceuticals Inc., MaxiVAX SA, Mebiopharm Co Ltd, MedImmune LLC, Merck & Co Inc, Merck KGaA, Merrimack Pharmaceuticals Inc, Mersana Therapeutics Inc, Merus NV, Mirati Therapeutics Inc, Molecular Partners AG, Molecular Targeting Technologies Inc, Moleculin Biotech Inc, MolMed SpA, NanoCarrier Co Ltd, Novartis AG, Novogen Ltd, OBI Pharma Inc, Oncobiologics Inc, Oncolys BioPharma Inc, OncoMed Pharmaceuticals Inc, OncoResponse Inc, Ono Pharmaceutical Co Ltd, Opsona Therapeutics Ltd, Patrys Ltd, Pfizer Inc, Pharma Mar SA, Pieris Pharmaceuticals Inc, Plexxikon Inc, Prescient Therapeutics Ltd, Puma Biotechnology Inc, Redx Pharma Plc, Rhizen Pharmaceuticals SA, Richter Gedeon Nyrt, Samumed LLC, Sanofi, Selecta Biosciences Inc, Sequella Inc, Shionogi & Co Ltd, Simcere Pharmaceutical Group, Sorrento Therapeutics Inc, Spectrum Pharmaceuticals Inc, Stelic Institute & Co Inc, Supratek Pharma Inc, SynCore Biotechnology Co Ltd, Synovo GmbH, Synthon Holdings BV, Taiho Pharmaceutical Co Ltd, Taiwan Liposome Company Ltd, Takis Srl, Tessa Therapeutics Pte Ltd, Transgene SA, Tyrogenex Inc, United BioPharma Inc, Vaxon Biotech, ViiV Healthcare Ltd, Viracta Therapeutics Inc, XuanZhu Pharma Co Ltd, Zymeworks Inc
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/772412-gastric-cancer-pipeline-review-1
Introduction 8
Gastric Cancer - Overview 9
Gastric Cancer - Therapeutics Development 10
Gastric Cancer - Therapeutics Assessment 45
Gastric Cancer - Companies Involved in Therapeutics Development 63
Gastric Cancer - Drug Profiles 133
Gastric Cancer - Dormant Projects 1047
Gastric Cancer - Discontinued Products 1056
Gastric Cancer - Product Development Milestones 1059
Appendix 1079List of Tables
....Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/772412-gastric-cancer-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
Contact Us:
CRAIG FRANCIS (PR & Marketing Manager)
[email protected]
Ph: +1 (206) 317 1218
#Gastric Cancer – Diseases & Therapeutic Pipeline Review#Gastric Cancer#Gastric Cancer – Diseases & Therapeutic
0 notes
Text
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40) Industry Research Report - Radiant Insights
According to the recently published report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017'; Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) pipeline Target constitutes close to 21 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.
Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) - Tumor Necrosis Factor Receptor Superfamily Member 5 is a member of the TNF-receptor superfamily. This protein is a receptor on antigen-presenting cells of the immune system and is essential for mediating a broad variety of immune and inflammatory responses including T cell-dependent immunoglobulin class switching, memory B cell development, and germinal center formation. The interaction of this receptor and its ligand is found to be necessary for amyloid-beta-induced microglial activation, and thus is thought to be an early event in Alzheimer disease pathogenesis.
Download Full Research Report @ https://www.radiantinsights.com/research/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen-cd40
The report 'Tumor Necrosis Factor Receptor Superfamily Member 5 - Pipeline Review, H2 2017' outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 6, 6, 4 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Gastrointestinal, Central Nervous System, Genito Urinary System And Sex Hormones, Hematological Disorders, Hormonal Disorders and Metabolic Disorders which include indications Solid Tumor, Crohn's Disease (Regional Enteritis), Kidney Transplant Rejection, Lymphoma, Melanoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Gastric Cancer, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Ovarian Cancer, Rheumatoid Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Bladder Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastroesophageal (GE) Junction Carcinomas, Graves Diseases, Heart Transplant Rejection, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Hyperthyroidism, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), Lupus Nephritis, Membranous Glomerulonephritis, Metastatic Adenocarcinoma of The Pancreas, Metastatic Melanoma, Metastatic Ovarian Cancer, Multiple Sclerosis, Myasthenia Gravis, Osteosarcoma, Pancreatic Islet Transplant Rejection, Primary Biliary Cirrhosis, Prostate Cancer, Renal Cell Carcinoma, Sicca Syndrome (Sjogren), Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Request a Free Sample Copy of this Report @ https://www.radiantinsights.com/research/tumor-necrosis-factor-receptor-superfamily-member-5-b-cell-surface-antigen-cd40/request-sample
Scope
• The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
• The report reviews Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) targeted therapeutics
Reasons To Buy
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 5 (B Cell Surface Antigen CD40 or Bp50 or CDw40 or CD40L Receptor or TNFRSF5 or CD40) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
See More Reports of This Category by Radiant Insights @
https://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email: [email protected]
visit our website: http://www.radiantinsights.com/
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco
State: California
Country: United States
0 notes
Text
RAC Beta Serine/ Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2. 7. 11. 1) Pipeline H1 2017 Review Market Landscape and Top Companies Analyzed Report
Description:
According to the recently published report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2017'; RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) pipeline Target constitutes close to 11 molecules. Out of which approximately 11 molecules are developed by Companies.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310024 .
RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) - RAC-beta serine/threonine-protein kinase is an enzyme encoded by the AKT2 gene. It plays a role as key modulator of the AKT-mTOR signaling pathway controlling the tempo of the process of newborn neurons integration during adult neurogenesis, including correct neuron positioning, dendritic development and synapse formation. AKT2 is also specifically involved in skeletal muscle differentiation, one of its substrates in this process being ANKRD2.
The report 'RAC Beta SerineThreonine Protein Kinase - Pipeline Review, H1 2017' outlays comprehensive information on the RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Browse the full report @ http://www.orbisresearch.com/reports/index/rac-beta-serine-threonine-protein-kinase-protein-kinase-akt-2-or-protein-kinase-b-beta-or-rac-pk-beta-or-akt2-or-ec-2-7-11-1-pipeline-review-h1-2017 .
It also reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I and Preclinical stages are 6, 2 and 3 respectively. Report covers products from therapy areas Oncology, Cardiovascular, Hematological Disorders, Non Malignant Disorders and Other Diseases which include indications Endometrial Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Breast Cancer, Cervical Cancer, Colorectal Cancer, Fallopian Tube Cancer, Metastatic Breast Cancer, Pancreatic Cancer, Peritoneal Cancer, Small-Cell Lung Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Melanoma, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Prostate Cancer, Thymoma (Thymic Epithelial Tumor), Anal Cancer, Brain Cancer, Colon Cancer, Congenital Vascular Malformation, Esophageal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Glioblastoma Multiforme (GBM), Hepatocellular Carcinoma, Leukemias, Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Hamartoma Syndrome, Neuroendocrine Cancer, Orphan Diseases, Proteus Syndrome, Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Renal Cell Carcinoma, Sickle Cell Disease, Soft Tissue Sarcoma and Solid Tumor.
Scope
- The report provides a snapshot of the global therapeutic landscape for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
- The report reviews RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)targeted therapeutics and enlists all their major and minor projects
- The report assesses RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1) targeted therapeutics
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310024 .
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding RAC Beta Serine/Threonine Protein Kinase (Protein Kinase Akt 2 or Protein Kinase B Beta or RAC PK Beta or AKT2 or EC 2.7.11.1)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Almac Discovery Ltd
ArQule Inc
AstraZeneca Plc
Bayer AG
Critical Outcome Technologies Inc
Merck & Co Inc
Novartis AG
For any enquires before buying, connect with us @ [email protected]
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact [email protected]
0 notes
Text
Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029 published on
https://www.sandlerresearch.org/gastric-and-gastroesophageal-junction-adenocarcinoma-global-drug-forecast-and-market-analysis-to-2029.html
Gastric and Gastroesophageal Junction Adenocarcinoma - Global Drug Forecast and Market Analysis to 2029
Gastric and Gastroesophageal Junction Adenocarcinoma – Global Drug Forecast and Market Analysis to 2029
Summary
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) is the fifth most common form of cancer and the fourth leading cause of cancer-related death worldwide, yet little is known about its exact etiology despite much ongoing research. Notably, G/GEJAC incidence rates are much higher in East Asia, particularly in Japan, China, and Korea. Approximately 90-95% of G/GEJACs are adenocarcinomas, while the rest represent rarer gastric malignancies, such as gastrointestinal stromal tumors, lymphomas, and neuroendocrine tumors. Historically, treatment of G/GEJAC has been mostly reliant on chemotherapy, with this remaining the mainstay for HER2-negative patients. Since 2010, the introduction of Roche’s Herceptin, Eli Lilly’s Cyramza and more recently BMS’s Opdivo and Merck’s Keytruda have allowed for this first sequential therapy option for these patients. GlobalData is expecting a total of 9 new entrants to launch over the forecast period in the 8MM from 2019-2029, while specific marketed agents are expected to move into earlier lines of treatment as novel combinations. The new competitive landscape will be driven by novel HER-2 targeting agents, novel biomarker-driven therapies and the label expansions of immunotherapies.
Key Highlights
– The main drivers of growth include the anticipated launch of novel HER2-targeting drugs, new drug classes and label expansions of currently marketed therapies across the 8MM during the forecast period.
– The main barriers to growth in the 8MM include the patent expiry of the market leading drugs.
– Among the late-stage pipeline products and marketed agents, marketed drug combinations, novel HER2-targeting agents and novel biomarker-led therapies are expected to generate the greatest revenues over the forecast period.
– The most important unmet needs in the G/GEJAC market include: the lack of approved therapies for metastatic patients, alternatives to chemotherapy in the neoadjuvant/adjuvant setting for resectable disease patients, the identification of widespread biomarkers and the adoption of a cost-effective screening programs.
KEY QUESTIONS ANSWERED
– Nine late-stage pipeline agents and five label expansions are going to enter the G/GEJAC market from 2019 onwards. What the impact will these agents have on the market? Which of these drugs will have the highest peak sales, and why?
– What are the current unmet needs in G/GEJAC, which pipeline agents are positioned to counter these unmet needs? What are the opportunities for R&D?
– What is the market outlook in the 8MM from 2019-2029? Considering major patent expiries, launch of new premium priced agents and expected label expansions.
Scope
– Overview of G/GEJAC including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and treatment guidelines.
– Topline G/GEJAC market revenue, annual cost of therapy, and major pipeline product sales in the forecast period.
– Key topics covered include current treatment and pipeline therapies, unmet needs and opportunities, and the drivers and barriers affecting G/GEJAC therapeutics sales in the 8MM.
– Pipeline analysis: Comprehensive data split across different phases, emerging novel trends under development, and detailed analysis of late-stage pipeline drugs (Phase III).
– Analysis of the current and future market competition in the global G/GEJAC therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to –
– Develop and design your in-licensing and out-licensing strategies, using a detailed overview of current pipeline products and technologies to identify companies with the most robust pipelines.
– Develop business strategies by understanding the trends shaping and driving the global G/GEJAC therapeutics market.
– Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global G/GEJAC market in the future.
– Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
– Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
– Track drug sales in the global G/GEJAC therapeutics market from 2019-2029.
– Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
0 notes
Text
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen) Industry Research Report - Radiant Insights
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) - Tumor Necrosis Factor Receptor Superfamily Member 4 or OX40 is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. OX40L binds to OX40 receptors on T-cells, preventing them from dying and subsequently increasing cytokine production. OX40 has a critical role in the maintenance of an immune response. OX40 also plays a crucial role in both Th1 and Th2 mediated reactions.
Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) pipeline Target constitutes close to 17 molecules. Out of which approximately 17 molecules are developed by Companies. The molecules developed by companies in Phase II, Phase I, Preclinical and Discovery stages are 5, 3, 5 and 4 respectively. Report covers products from therapy areas Oncology, Immunology, Dermatology, Gastrointestinal and Metabolic Disorders which include indications Solid Tumor, Head And Neck Cancer Squamous Cell Carcinoma, Non-Small Cell Lung Cancer, Bladder Cancer, Melanoma, Renal Cell Carcinoma, Atopic Dermatitis, Breast Cancer, Cervical Cancer, Colorectal Cancer, Endometrial Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hematological Tumor, Metastatic Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Melanoma, Metastatic Ovarian Cancer, Metastatic Renal Cell Carcinoma, Soft Tissue Sarcoma, Systemic Lupus Erythematosus, Transplant Rejection, Type 1 Diabetes (Juvenile Diabetes) and Ulcerative Colitis.
Download Full Research Report @ https://www.radiantinsights.com/research/tumor-necrosis-factor-receptor-superfamily-member-4-act35-antigen
The latest report Tumor Necrosis Factor Receptor Superfamily Member 4 - Pipeline Review, H2 2017, outlays comprehensive information on the Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Scope :
• The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
• The report reviews Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
• The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
• The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
• The report reviews key players involved in Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics and enlists all their major and minor projects
• The report assesses Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
• The report summarizes all the dormant and discontinued pipeline projects
• The report reviews latest news and deals related to Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) targeted therapeutics
Request a Free Sample Copy of this Report @ https://www.radiantinsights.com/research/tumor-necrosis-factor-receptor-superfamily-member-4-act35-antigen/request-sample
Reasons To Buy:
• Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4)
• Identify the use of drugs for target identification and drug repurposing
• Identify potential new clients or partners in the target demographic
• Develop strategic initiatives by understanding the focus areas of leading companies
• Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
• Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Receptor Superfamily Member 4 (ACT35 Antigen or TAX Transcriptionally Activated Glycoprotein 1 Receptor or OX40L Receptor or CD134 or TNFRSF4) development landscape
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
See More Reports of This Category by Radiant Insights @
https://www.radiantinsights.com/catalog/pharmaceuticals-and-healthcare
About Radiant Insights
Radiant Insights is a platform for companies looking to meet their market research and business intelligence requirements. It assist and facilitate organizations and individuals procure market research reports, helping them in the decision making process. The Organization has a comprehensive collection of reports, covering over 40 key industries and a host of micro markets. In addition to over extensive database of reports, experienced research coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research solutions.
Media Contact:
Company Name: Radiant Insights, Inc
Contact Person: Michelle Thoras
Email: [email protected]
visit our website: http://www.radiantinsights.com/
Phone: (415) 349-0054
Toll Free: 1-888-928-9744
Address: 201 Spear Street 1100, Suite 3036,
City: San Francisco
State: California
Country: United States
0 notes
Text
Global Market Study On Phosphatidylinositol 4, 5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4, 5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2. 7. 1. 153) - Pipeline Review, H1 2017
Description:
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) - Phosphatidylinositol-4, 5-bisphosphate 3-kinase catalytic subunit beta isoform is an enzyme encoded by the PIK3CB gene. It is involved in cell growth, survival, proliferation, motility and morphology. It participates in cellular signaling in response to various growth factors. It is involved in the activation of AKT1 and signaling via insulin-receptor substrate (IRS) proteins. It is required for lymphatic vasculature development, different signaling pathways for stable platelet adhesion and aggregation. It plays an important role in platelet activation.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310025 .
Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) pipeline Target constitutes close to 13 molecules. Out of which approximately 12 molecules are developed by companies and remaining by the universities/institutes. The molecules developed by companies in Phase II, Phase I and Preclinical stages are 4, 3 and 5 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Cardiovascular, Central Nervous System, Dermatology and Ophthalmology which include indications Solid Tumor, Breast Cancer, Diffuse Large B-Cell Lymphoma, Endometrial Cancer, Glioblastoma Multiforme (GBM), Lymphoma, Ovarian Cancer, Follicular Lymphoma, Head And Neck Cancer Squamous Cell Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Multiple Myeloma (Kahler Disease), Neuroblastoma, Non-Small Cell Lung Cancer, Pancreatic Cancer, Prostate Cancer, Relapsed Chronic Lymphocytic Leukemia (CLL), Squamous Non-Small Cell Lung Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), B-Cell Non-Hodgkin Lymphoma, Burkitt Lymphoma, CNS Lymphoma, Colorectal Cancer, Gastric Cancer, Gastrointestinal Stromal Tumor (GIST), Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Lung Cancer, Mantle Cell Lymphoma, Melanoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Metastatic Transitional (Urothelial) Tract Cancer, Myelofibrosis, NUT Midline Carcinoma (NMC or Nuclear Protein in Testis Midline Carcinoma), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary CNS Lymphoma, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia (CLL), Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Thrombocythemia Myelofibrosis, Thrombosis, Thymoma (Thymic Epithelial Tumor) and Thyroid Cancer.
The latest report Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform - Pipeline Review, H1 2017, outlays comprehensive information on the Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics development with respective active and dormant or discontinued projects.
The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Browse the full report @ http://www.orbisresearch.com/reports/index/phosphatidylinositol-4-5-bisphosphate-3-kinase-catalytic-subunit-beta-isoform-phosphatidylinositol-4-5-bisphosphate-3-kinase-110-kda-catalytic-subunit-beta-or-pik3cb-or-ec-2-7-1-153-pipeline-review-h1-2017 .
Scope
- The report provides a snapshot of the global therapeutic landscape for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
- The report reviews Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)targeted therapeutics and enlists all their major and minor projects
- The report assesses Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Phosphatidylinositol 4,5 Bisphosphate 3 Kinase Catalytic Subunit Beta Isoform (Phosphatidylinositol 4,5 Bisphosphate 3 Kinase 110 kDa Catalytic Subunit Beta or PIK3CB or EC 2.7.1.153)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310025 .
Companies Mentioned
AstraZeneca Plc
Bayer AG
Curis Inc
GlaxoSmithKline Plc
Karus Therapeutics Ltd
Novartis AG
PIQUR Therapeutics AG
For any enquires before buying, connect with us @ [email protected]
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact [email protected]
0 notes
Text
Increasing Prevalence of Diseases to Boost Demand for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017
Description:
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) pipeline Target constitutes close to 22 molecules. Out of which approximately 22 molecules are developed by Companies. The latest report Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Pipeline Review, H1 2017, outlays comprehensive information on the Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310031 .
Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) - Lymphocyte-activation gene 3 or LAG-3 is a protein encoded by the LAG3 gene. It is involved in the maturation and activation of dendritic cells and lymphocyte activation. It binds to HLA class-II antigens. The molecules developed by companies in Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 2, 5, 2, 8 and 5 respectively. Report covers products from therapy areas Oncology, Immunology, Cardiovascular and Infectious Disease which include indications Solid Tumor, Non-Small Cell Lung Cancer, Autoimmune Disorders, Lymphoma, Melanoma, Advanced Malignancy, Bladder Cancer, Blood Cancer, Cardiovascular Disease, Cervical Cancer, Chronic Inflammation, Colorectal Cancer, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Gastric Cancer, Gliosarcoma, Head And Neck Cancer Squamous Cell Carcinoma, Hepatocellular Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Inflammation, Kidney Cancer (Renal Cell Cancer), Non-Hodgkin Lymphoma, Ovarian Cancer, Plaque Psoriasis (Psoriasis Vulgaris), Recurrent Glioblastoma Multiforme (GBM), Refractory Chronic Lymphocytic Leukemia (CLL), Refractory Multiple Myeloma, Relapsed Chronic Lymphocytic Leukemia (CLL), Relapsed Multiple Myeloma and Renal Cell Carcinoma.
Furthermore, this report also reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.
Browse the full report @ http://www.orbisresearch.com/reports/index/lymphocyte-activation-gene-3-protein-protein-fdc-or-cd223-or-lag3-pipeline-review-h1-2017 .
Scope
- The report provides a snapshot of the global therapeutic landscape for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- The report reviews Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)targeted therapeutics and enlists all their major and minor projects
- The report assesses Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3) targeted therapeutics
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Lymphocyte Activation Gene 3 Protein (Protein FDC or CD223 or LAG3)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310031 .
Companies Mentioned
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Crescendo Biologics Ltd
Enumeral Biomedical Holdings Inc
GlaxoSmithKline Plc
Icell Kealex Therapeutics
Incyte Corp
MacroGenics Inc
Merck & Co Inc
Novartis AG
Prima BioMed Ltd
Regeneron Pharmaceuticals Inc
Sutro Biopharma Inc
Symphogen A/S
Tesaro Inc
Trellis Bioscience Inc
Xencor Inc
For any enquires before buying, connect with us @ [email protected]
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact [email protected]
0 notes
Text
H1 2017, Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2. 7. 11. 22) Pipeline Market Landscape Review Report
Description:
According to the recently published report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017'; Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes.
Request a sample of this report @ http://www.orbisresearch.com/contacts/request-sample/310020 .
Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) - Cyclin-dependent kinase 4 is an enzyme encoded by the CDK4 gene. Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G1/S transition. Activation of the cyclin-D-CDK4 complex appears to require other factors such as recruitment of the substrate via a substrate recruitment motif, and/or formation of the CDKN1B ternary complex.
The report 'Cyclin Dependent Kinase 4 - Pipeline Review, H1 2017' outlays comprehensive information on the Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
Browse the full report @ http://www.orbisresearch.com/reports/index/cyclin-dependent-kinase-4-cell-division-protein-kinase-4-or-psk-j3-or-cdk4-or-ec-2-7-11-22-pipeline-review-h1-2017 .
It also reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 3, 2, 12 and 2 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Genito Urinary System And Sex Hormones and Toxicology which include indications Breast Cancer, Metastatic Breast Cancer, Mantle Cell Lymphoma, Non-Small Cell Lung Cancer, Lymphoma, Colon Cancer, Colorectal Cancer, Hepatocellular Carcinoma, Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Liposarcoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Melanoma, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Solid Tumor, Thymic Carcinoma, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Acute Renal Failure (ARF) (Acute Kidney Injury), Anaplastic Oligoastrocytoma, Bacterial Infections, Chemotherapy Induced Myelosuppression, Dedifferentiated Liposarcoma, Diffuse Large B-Cell Lymphoma, Duodenal Cancer, Endometrial Cancer, Epithelial Ovarian Cancer, Epstein-Barr Virus (HHV-4) Infections, Fallopian Tube Cancer, Gastric Cancer, Germ Cell Tumors, Glioblastoma Multiforme (GBM), Head And Neck Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Hematological Tumor, Leukemias, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Brain Tumor, Metastatic Colorectal Cancer, Metastatic Hepatocellular Carcinoma (HCC), Metastatic Transitional (Urothelial) Tract Cancer, Multiple Myeloma (Kahler Disease), Myelosuppression, Neuroblastoma, Neuroendocrine Tumors, Oligodendroglioma, Oropharyngeal Cancer, Peritoneal Cancer, Prostate Cancer, Recurrent Glioblastoma Multiforme (GBM), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Relapsed Multiple Myeloma, Rheumatoid Arthritis, Small-Cell Lung Cancer and Squamous Non-Small Cell Lung Cancer.
Scope
- The report provides a snapshot of the global therapeutic landscape for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- The report reviews Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics and enlists all their major and minor projects
- The report assesses Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22) targeted therapeutics
Purchase a copy of this report @ http://www.orbisresearch.com/contact/purchase/310020 .
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cyclin Dependent Kinase 4 (Cell Division Protein Kinase 4 or PSK J3 or CDK4 or EC 2.7.11.22)development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Companies Mentioned
Beta Pharma Inc
Eli Lilly and Company
FLX Bio Inc
G1 Therapeutics Inc
Jiangsu Hengrui Medicine Co Ltd
Novartis AG
Onconova Therapeutics Inc
Pfizer Inc
Teijin Pharma Ltd
Tiziana Life Sciences Plc
ViroStatics srl
XuanZhu Pharma Co Ltd
For any enquires before buying, connect with us @ [email protected]
About Us:
Orbis Research (orbisresearch.com) is a single point aid for all your market research requirements. We have vast database of reports from the leading publishers and authors across the globe. We specialize in delivering customized reports as per the requirements of our clients. We have complete information about our publishers and hence are sure about the accuracy of the industries and verticals of their specialization. This helps our clients to map their needs and we produce the perfect required market research study for our clients.
Contact Us:
Hector Costello
Senior Manager – Client Engagements
4144N Central Expressway,
Suite 600, Dallas,
Texas - 75204, U.S.A.
Phone No.: +1 (214) 884-6817; +912064101019
For more information contact [email protected]
0 notes
Last Seen Blogs
